Refine Search
(179)
(196)
(753)
(1689)

The Biopharmaceutical Industry in 2017: Highlights by Therapeutic Area

  • $275
  • February 2018
Add to Basket Quick View Add to Saved List

For the biopharmaceutical industry, 2017 was marked by noteworthy innovation as well as disappointments across therapy areas, set against a backdrop of remarkable advances in technology in healthcare and the growing presence of biosimilars. Eac...

PharmSource - Mixed Signals: Understanding the Outlook for Pharma R&D Spending Through 2015

  • $295
  • February 2014
Add to Basket Quick View Add to Saved List

The pharmaceutical R&D services market is sending conflicting signals: new clinical trial starts are down, IPOs are up and start-ups are having trouble raising funding. With such contradictory information, how can R&D service providers ...

FDA Approves Erivedge (Vismodegib) for Metastatic or Locally Advanced Basal Cell Carcinoma

  • $500
  • February 2012
Add to Basket Quick View Add to Saved List

GlobalData, the industry analysis specialist, has released its new view point, “FDA Approves Erivedge (vismodegib) for Metastatic or Locally Advanced Basal Cell Carcinoma”. The report is an essential source of information on the approval of Eri...

Impact of Eurozone Crisis on Healthcare Economics

  • $500
  • February 2012
Add to Basket Quick View Add to Saved List

GlobalData, the industry analysis specialist, has released its new view point, “Impact of Eurozone Crisis on Healthcare Economics”. The report is an essential source of information for the analysis on the impact of the Eurozone crisis on the he...

Xgeva’s Safety and Efficacy Failings Put Future of Amgen Drug in Question

  • $500
  • February 2012
Add to Basket Quick View Add to Saved List

GlobalData, the industry analysis specialist, has released its new viewpoint, “Xgeva’s Safety and Efficacy Failings Put Future of Amgen Drug in Question”. The report is an essential source of information for the analysis of scope of approval fo...

Approval of Kalydeco Brings New Hope for CF Patients with G551D Mutation

  • $500
  • February 2012
Add to Basket Quick View Add to Saved List

The viewpoint is an essential source of information and analysis on the KALYDECO (ivacaftor, VX-770) for the treatment of Cystic Fibrosis (CF) patients with G551D mutation. The viewpoint provides insights on the product clinical information and...

Which Strategies can Big Pharmaceutical Companies Use to Manage the Impact of Patent Protection Loss?

  • $500
  • January 2012
Add to Basket Quick View Add to Saved List

The viewpoint is an essential source of information and analysis on the patent protection strategies by Big Pharma along with the case studies. The viewpoint provides insights on the companies as well as products that were launched to minimise ...

Tensions Rising between Branded Drugmakers and Health Plans

  • $500
  • March 2012
Add to Basket Quick View Add to Saved List

GlobalData's new alert "Tensions Rising between Branded Drugmakers and Health Plans" analyzes the Co-Pay Coupon lawsuit and the implications for branded drugmakers and health plan providers. Large pharmaceutical companies are in t...

Breaking the Gene Therapy Barrier for Life-Threatening Red Blood Cell Disorders

  • $500
  • April 2012
Add to Basket Quick View Add to Saved List

GlobalData’s new alert, “Breaking the Gene Therapy Barrier for Life-Threatening Red Blood Cell Disorders” takes a look at gene therapy for the treatment of blood disorders such as beta-thalassemia and sickle cell anemia. An international team o...

A Tale of Two Multiple Myeloma Therapies - The Race for Accelerated Approval

  • $500
  • May 2012
Add to Basket Quick View Add to Saved List

Multiple myeloma patients with relapsed and refractory disease are underserved by current pharmaceutical offerings. Two drugs, Onyx’s proteasome inhibitor carfilzomib and Celgene’s immunomodulatory drug pomalidomide, are currently being evalua...

Afinitor - A Two-Pronged Attack Against Tuberous Sclerosis Complex

  • $500
  • May 2012
Add to Basket Quick View Add to Saved List

GlobalData’s new alert, Afinitor: A Two-Pronged Attack Against Tuberous Sclerosis Complex,” takes a look at the implications of the FDA’s recent approval of the drug for the treatment of angiomyolipomas, benign kidney tumors that affect a major...

The Biopharmaceutical Industry in 2018: Key Events and Trends to Watch for by Therapy Area

  • $500
  • March 2018
Add to Basket Quick View Add to Saved List

2018 promises to be a year of continued innovation in the biopharmaceutical industry across therapy areas. In this report, GlobalData’s analysts highlight a selection of highly anticipated events, including regulatory approvals, product launche...

Brexit and the Healthcare Industry – Implications for Pharma, Q3 2018

  • $500
  • November 2018
Add to Basket Quick View Add to Saved List

It has been over two years since the UK voted to leave the EU. As Brexit deadlines loom, negotiations are still ongoing to determine the UK’s relationship with the EU after Brexit.

This report provides an assessment of how the pharmaceuti...

Brexit and the Healthcare Industry – Implications for Pharma, Q1 2018

  • $500
  • May 2018
Add to Basket Quick View Add to Saved List

It has been almost two years since the UK voted to leave the EU. Businesses were told a vote to leave the EU would drive the UK into a severe recession, yet markets are up. Negotiations are ongoing to determine the UK’s post-Brexit relationship...

General Data Protection Regulation (GDPR) in the Healthcare Industry – Implications for Healthcare – H1 2018

  • $500
  • July 2018
Add to Basket Quick View Add to Saved List

The EU voted to implement updated data protection laws in the form of the General Data Protection Regulation (GDPR) in April 2016. GDPR came into force on May 25, 2018, providing EU citizens with greater rights and control regarding the process...

Join our mailing list
Find out first about the latest reports and offers.
Report Catalogue

Strategic Insight Reports

Market Analysis Reports

Databooks